Antitumor therapies awake the cGAS-STING signaling to accelerate the antitumor immunity
Antitumor therapies awake the cGAS-STING signaling to accelerate the antitumor immunity. Features of the tumor microenvironment like chromatin instability and growth stress can cause cytoplasmic or extracellular accumulation of dsDNA to activate the cGAS-STING pathway. Similarly, anti-tumor therapies such as radiotherapy and chemotherapy can also cause accumulation of genomic or mitochondria-derived dsDNA in the cytosol. Tumor-derived cGAMP can also secrete into the TME, and enter immune cells via the folate transporter SLC19A1. However, DNA damage recruits the cGAS translocating to nuclear and inhibits the homologous recombination by interfering the PARP1-timeless complex formation. On the other hand, antitumor therapies also upregulate negative regulators of cGAS-STING, as CASP9 signaling, to suppress the activation of the intrinsic cGAS-STING pathway. Therefore, targeting such negative regulators or delivery of STIGN agonists could specifically activate the cGAS-STING signaling in the TME. This will help to upregulate the expression of Th1 chemokines (CXCL9 and CXCL10) and antigen presenting molecules (MHCI), recruit CD8+T cells, and activate innate immune cells. However, the increase of IFN secretion may also enhance the infiltration of MDSC and upregulate PD-L1 and other immunosuppressive factors to exert an inhibitory effect. dsDNA, double-stranded DNA; cGAS, GMP-AMP synthase; SITNG, stimulator of interferon genes; cGAMP, cyclic GMP-AMP; CASP, caspase; TME, tumor microenvironment; MDSC, monocyte-derived suppressor cells